fosphenytoin (Q5473363)

Fosphenytoin (English)

18 November 2016

chemical formula

C₁₆H₁₅N₂O₆P

1 reference

Fosphenytoin (English)

18 November 2016

canonical SMILES

C1=CC=C(C=C1)C2(C(=O)N(C(=O)N2)COP(=O)(O)O)C3=CC=CC=C3

1 reference

Fosphenytoin (English)

parenteral route of administration

18 November 2016

defined daily dose

0.45 gram

route of administration

1 reference

reference URL

https://www.whocc.no/atc_ddd_index/?code=N03AB05

1 reference

14 February 2018

World Health Organisation international non-proprietary name

Fosphenytoin (English)

1 reference

Fosphenytoin (English)

medical condition treated

19 January 2016

1 reference

13 December 2016

1 reference

Drug Indications Extracted from FAERS

13 December 2016

1 reference

significant drug interaction

2 October 2018

vincristine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

amiodarone

1 reference

A reference set of clinically relevant adverse drug-drug interactions

bortezomib

1 reference

A reference set of clinically relevant adverse drug-drug interactions

paclitaxel

1 reference

A reference set of clinically relevant adverse drug-drug interactions

cisplatin

1 reference

A reference set of clinically relevant adverse drug-drug interactions

metronidazole

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

vinblastine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

L-thyroxine

hypothyroidism

1 reference

A reference set of clinically relevant adverse drug-drug interactions

dronedarone

1 reference

A reference set of clinically relevant adverse drug-drug interactions

sertraline

1 reference

A reference set of clinically relevant adverse drug-drug interactions

amiodarone

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

dasatinib monohydrate

1 reference

A reference set of clinically relevant adverse drug-drug interactions

metronidazole

1 reference

A reference set of clinically relevant adverse drug-drug interactions

metronidazole

heart arrhythmia

1 reference

A reference set of clinically relevant adverse drug-drug interactions

saquinavir

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

pazopanib

1 reference

A reference set of clinically relevant adverse drug-drug interactions

vandetanib

1 reference

A reference set of clinically relevant adverse drug-drug interactions

vemurafenib

1 reference

A reference set of clinically relevant adverse drug-drug interactions

dabrafenib

1 reference

A reference set of clinically relevant adverse drug-drug interactions

crizotinib

1 reference

A reference set of clinically relevant adverse drug-drug interactions

ivabradine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

fluoxetine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

aripiprazole

1 reference

A reference set of clinically relevant adverse drug-drug interactions

quetiapine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

tacrolimus

1 reference

A reference set of clinically relevant adverse drug-drug interactions

legal status (medicine)

boxed warning

1 reference

reference URL

https://nctr-crs.fda.gov/fdalabel/ui/spl-summaries/criteria/343802

imported from Wikimedia project

FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links. (English)

pregnancy category

US pregnancy category D

1 reference

1 reference

Medical Subject Headings

15 March 2018

Fosphenytoin

0 references

Identifiers

InChI

InChI=1S/C16H15N2O6P/c19-14-16(12-7-3-1-4-8-12,13-9-5-2-6-10-13)17-15(20)18(14)11-24-25(21,22)23/h1-10H,11H2,(H,17,20)(H2,21,22,23)

1 reference

Fosphenytoin (English)

XWLUWCNOOVRFPX-UHFFFAOYSA-N

18 November 2016

InChIKey

2 references

Fosphenytoin (English)

18 November 2016

ChEBI release 2020-09-01

CAS Registry Number

93390-81-9

2 references

fosphenytoin (English)

XWLUWCNOOVRFPX-UHFFFAOYSA-N

18 November 2016

InChIKey

9 April 2021

https://commonchemistry.cas.org/detail?cas_rn=93390-81-9

1 reference

(2,5-Dioxo-4,4-diphenyl-1-imidazolidinyl)methyl dihydrogen phosphate (English)

18 November 2016

1 reference

Fosphenytoin (English)

18 November 2016

ChEBI ID

5165

mapping relation type

1 reference

FOSPHENYTOIN (English)

18 November 2016

1 reference

Hazardous Substances Data Bank

FOSPHENYTOIN (English)

18 November 2016

1 reference

1 reference

28 October 2019

FOSPHENYTOIN (English)

10 May 2021

1 reference

Mapping file of InChIStrings, InChIKeys and DTXSIDs for the EPA CompTox Dashboard

DSSTOX compound identifier

0 references

1 reference

Guide to Pharmacology Ligand ID

Fosphenytoin (English)

publication date

17 November 2015

7190

1 reference

IUPHAR/BPS Guide to PHARMACOLOGY

Guide to Pharmacology Ligand ID

7190

fosphenytoin (English)

18 November 2016

1 reference

Medical Subject Headings

14 March 2018

1 reference

fosphenytoin (English)

18 November 2016

1 reference

Fosphenytoin (English)

18 November 2016

1 reference

fosphenytoin (English)

MedlinePlus drug identifier

18 November 2016

a619063

0 references

PatientsLikeMe treatment ID

0 references

1 reference

fosphenytoin (English)

18 November 2016

0 references

1 reference

1 reference

Fosphenytoin (English)

3 October 2016

1 reference

Fosphenytoin (English)

3 October 2016

Freebase ID

/m/073l73

0 references

Microsoft Academic ID

0 references

1 reference

fosphenytoin (English)